Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AlphaMed, Inc.
National Cancer Institute awards grant for targeted radiotherapy development
September 10th, 2003
AlphaMed, Inc., announced that it has received a $500,000 2-year STTR phase II grant award from the National Cancer Institute to further develop a targeted radiotherapy for metastatic melanoma. AlphaMed is collaborating with the University of Missouri in Columbia in this work. The therapy is based on a molecule, labeled with the therapeutic radionuclide lead-212, that is selective to metastatic melanoma cells. Lead-212 decays to bismuth-212, which in turn emits an alpha particle that destroys tumor cells on contact. While melanoma is understood to be relatively radioresistant, alpha particles, with their high-energy deposition, may be effective in metastatic melanoma,...
Source: Biotech Week (2003-09-10)
|
